Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 3Phase 1/2 3Phase EARLY_PHASE1 1Phase 3 1Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 5Vomiting 1Renal Insufficiency 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Plasmacytoma 1POEMS Syndrome 1Obesity 1Neurotoxicity Syndromes 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Nausea 1Lymphoma, T-Cell, Peripheral 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Large Granular Lymphocytic 1Immunoglobulin Light-chain Amyloidosis 1Brain Neoplasms 1Amyloidosis 1Alzheimer Disease 1

Interventions

Rituximab 2venetoclax 1tafasitamab 1pembrolizumab 1glofitamab 1fludarabine 1avelumab 1Valproic Acid 1Melphalan 1Ifosfamide 1Gemcitabine 1Etoposide 1Dexamethasone 1Cyclophosphamide 1Cisplatin 1Carboplatin 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Lymphoma, B-Cell × Dexamethasone × Clear all
NCT04161248 2026-05-12

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Canadian Cancer Trials Group

Phase EARLY_PHASE1 Active not recruiting
40 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡